Collaboration Agreement Signed - Replacement

Oxford Biomedica PLC
20 January 2000

The issuer has advised that the 'Collaboration Agreement Signed' announcement
released today at 11:08 under RNS No 1156E contained a number of errors.

A full corrected version of the announcement is shown below with asterisks (*)
denoting paragraphs amended.
-------------------------------------------------------------------------------

For further information, please contact
Oxford BioMedica plc
Professor Alan Kingsman, Chief Executive
Tel: [phone]

City / Financial Enquiries
David Simonson / Melanie Toyne Sewell
Merlin Financial Communications
Tel: [phone]

*Scientific / Trade press Enquiries
 Sue Charles / Sarah Pattinson, HCC De Facto
 Tel: [phone]

IDM S.A.
Jean-Loup Romet-Lemonne, MD, President and CEO
Tel: [phone]

                            
*OXFORD BIOMEDICA AND IDM ANNOUNCE STRATEGIC COLLABORATION
    TO DEVELOP NEW CELL-BASED THERAPY PROGRAMMES

*Oxford, England, and Paris, France - 20 January 2000.
 Oxford BioMedica plc (AIM-OXB) and Immuno-Designed
 Molecules S.A. (IDM) today announced that they have
 signed an agreement, whereby the two companies will co-
 develop new cell-based therapy programmes.  This collaboration underlines
 Oxford BioMedica's strategy of applying its core gene therapy technology to
 other fields including that of gene-based immunotherapy.

*Cell-based therapy is a powerful approach to fighting
 diseases including cancer that uses cells from a
 patient's own immune system. It works by
 removing cells from a patient, manipulating them to increase their immune
 potential, and re-introducing them to the patient.

 Oxford BioMedica has developed novel methods for genetic
 engineering of patients' immune cells for the treatment
 of tumours. It is also developing therapeutic cancer
 vaccines which use potent tumour antigens.

*IDM has developed Cell Drugs which are produced using
 patient-dedicated Cell Processors.  IDM's Cell Processor
 technology allows the safe manipulation of patients'
 immune cells to become a routine hospital process, so
 speeding up the clinical development of cell-based
 therapy. 

*The combination of the two company's technologies
 will create new product programmes which should move rapidly into clinical
 development. Early products from the collaboration could be a series of novel
 vaccines against cancer and other diseases.  Under the terms of the
 collaboration Oxford BioMedica and IDM will jointly develop novel
 therapeutics, and will share the revenues from such products. This agreement
 should extend the reach of each company's technologies into new therapeutic
 markets.

*Commenting on the collaboration, BioMedica's Chief
 Executive, Professor Alan Kingsman, said:
 'IDM have developed a leading position in cell-based
 therapy with their clinically approved cell processor.
 This will make cell-based therapy a reality and provide
 us with a means of getting our technologies such as
 MacroGen and LentiVectors into cell-based products
 much faster. This is an excellent deal and it fits well 
 with our increasing activity in immunotherapy via gene
 delivery.'

*Dr. Jean-Loup Romet-Lemonne, IDM's President and CEO,
 said:
 'BioMedica has first class gene transfer technology and
 some novel approaches to identifying new tumour antigens.
 Together, we can develop new exciting Cell Drugs in the field of immunotherapy
 that would not otherwise have been possible.'
 
Notes to Editors

1.   Oxford BioMedica plc
     Established in 1995, the Company specialises in the
     development and application of gene-based
     therapeutics using advance gene delivery
     technologies for the treatment of disease in the
     areas of Oncology, Viral Infection and Neurobiology.
     Oxford BioMedica plc was floated on the UK
     Alternative Investment Market of the London Stock
     Exchange in December 1996.  For more information
     about the company visit its Web site at
     http://www.oxfordbiomedica.co.uk

*2.  IDM
     IDM is a privately owned biopharmaceutical company
     developing new cell and gene therapy treatments to
     fight cancer and other life-threatening diseases.
     IDM applies its proprietary technologies to
     selectively isolate, engineer, expand and activate
     specific cell populations which are involved in
     therapeutic vaccination. IDM's products are designed
     to boost the immune system, destroy residual tumour
     cells, and immunise patients to prevent
     tumour recurrence. For more information about the
     company visit its Web site at http://www.idm-
     biotech.com.
     
*3  IDM Cell Processors
    IDM's cell processors are single-use medical devices
    which contain all the necessary chemicals, devices,
    and quality control reagents for the preparation of
    standardised cell therapy products. An additional
    key feature of IDM's cell processors is their
    accompanying Lab Quality System software designed to
    guide the user at every stage in the cell
    preparation process, providing built-in safeguards
    to ensure the final product meets or exceeds
    required quality specifications for autologous
    immunotherapy. IDM's MAK Cell Processor has
    received CE Marking and is currently being used to
    prepare Cell Drugs in several clinical trials.

4    Gene-based Immunotherapy
     Gene-based immunotherapy seeks to treat disease by
     modulating (either increasing or reducing) a
     patient's immune responses using advanced gene
     delivery techniques. Immune responses are an
     important  factor in the development of a wide range
     of diseases including cancer, auto-immune diseases
     such as arthritis and infectious disease.
     
*5   Oxford BioMedica's LentiVector and MacroGen Technology
     Through its proprietary LentiVectorT systems Oxford
     BioMedica is able to efficiently deliver therapeutic
     genes to a wide range of cell types, including cells
     of the immune system.
     
    The MacroGen programme uses advanced gene delivery
    techniques to introduce therapeutic genes to
    macrophages, an important class of white blood
    cells. Macrophages modified in this way have
    properties which make them important candidates for
    the treatment of diseases including cancer and auto-
    immune diseases.
    
6   Worldwide web
    This release is also available on the Worldwide Web
    at http://www.oxfordbiomedica.co.uk